Unrelated Donor Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: Long-Term Outcomes
Autor: | Parameswaran Hari, Jeanette Carreras, Koen van Besien, Brent R. Logan, Philip J. Bierman, Richard E. Champlin, Hillard M. Lazarus, Joseph W. Fay, Roberta King, Gene Nelson, Julie M. Vose, Arturo Molina |
---|---|
Rok vydání: | 2009 |
Předmět: |
Male
Oncology Transplantation Conditioning Lymphoma medicine.medical_treatment Follicular lymphoma Graft vs Host Disease Hematopoietic stem cell transplantation 0302 clinical medicine Risk Factors hemic and lymphatic diseases Cumulative incidence Child Myeloablative Lymphoma Non-Hodgkin Hematopoietic Stem Cell Transplantation Hematology Middle Aged Tissue Donors 3. Good health Treatment Outcome Child Preschool 030220 oncology & carcinogenesis Female Adult Unrelated donor medicine.medical_specialty Adolescent Article Young Adult 03 medical and health sciences Age Distribution Internal medicine medicine Humans Transplantation Homologous Survival analysis Aged Retrospective Studies Transplantation business.industry medicine.disease Survival Analysis Peripheral T-cell lymphoma Surgery business Follow-Up Studies 030215 immunology |
Zdroj: | Biology of Blood and Marrow Transplantation. 15:554-563 |
ISSN: | 1083-8791 |
Popis: | We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma (NHL) facilitated by the Center for International Blood and Marrow Transplant Research/National Marrow Donor Program (CIBMTR/NMDP) between 1991 and 2004. All patients received myeloablative conditioning regimens. The median follow-up of survivors is 5 years. Seventy-three (26%) patients are alive. The day 100 probability of death from all causes is estimated at 39%. The cumulative incidence of developing grade III-IV acute graft-versus-host disease (aGVHD) at day 100 is 25%. The estimated 5-year survival and failure free survival are 24% (95% confidence interval [CI]: 19-30) and 22% (95% CI: 17-28), respectively. Factors adversely associated with overall survival (OS) included increasing age, decreased performance status, and refractory disease. Follicular lymphoma (FL) and peripheral T cell lymphoma had improved survival compared to aggressive B cell lymphomas. Factors adversely associated with progression-free survival (PFS) included performance status, histology, and disease status at transplant. Long-term failure-free survival is possible following unrelated donor transplantation for NHL, although early mortality was high in this large cohort. |
Databáze: | OpenAIRE |
Externí odkaz: |